Jorge J. Gumucio, Jonathan D. Kaunitz – 1 April 1991 – The “liver” isoform of the facilitated diffusion glucose transporter is expressed predominantly in liver, intestine, kidney, and pancreatic islet α‐cells. The apparent molecular mass of the transporter in liver, kidney, and intestine is different, as detected by Western blot analysis of membrane proteins using antipeptide antibodies.
Jorge J. Gumucio, Bahri Bilir, Jorge J. Gumucio – 1 April 1991 – The “erythroid/brain” glucose transporter (GT) isoform is expressed only in a subset of hepatocytes, those forming the first row around the terminal hepatic venules, while the “liver” GT is expressed in all hepatocytes. After 3 d of starvation, a three‐ to fourfold elevation of expression of the erythroid/brain GT mRNA and protein is detected in the liver as a whole; this correlates with the expression of this GT in more hepatocytes, those forming the first three to four rows around the hepatic venules.
Jorge J. Gumucio, Robert P. Perillo – 1 April 1991 – To identify previously unrecognized sources for acquiring acute hepatitis B and non‐A, non‐B (NANB) hepatitis, we interviewed patients with these types of hepatitis who were reported to two county health departments in the United States and matched control subjects for known and potential risk factors for acquiring hepatitis. Of 218 patients with hepatitis B and 140 patients with NANB hepatitis, 46% and 53%, respectively, had no commonly recognized source for infection.
1 April 1991
Christian Gluud, Harold O. Conn, L. S. Eriksson – 1 April 1991
Thomas P. Almdal, Thorkild I. A. Sørensen – 1 April 1991 – The sex‐specific and age‐specific incidence rates of the major parenchymal liver diseases in a North European population were estimated using a computerized registry of all admissions to somatic hospitals in Denmark.
Francesco Salerno, Salvatore Badalamenti, Elettra Lorenzano, Pamela Moser, Pierluigi Incerti – 1 April 1991 – Fifty‐four cirrhotic patients with refractory ascites were treated with one‐session large‐volume paracentesis and randomly assigned to two groups. The first group was infused with human albumin, and the second group was infused with hemaccel at doses with comparable oncotic power. The two groups were compared for incidence of complications, recurrence of massive ascites after hospital dismissal and survival rate.
John R. Lake, Teresa L. Wright – 1 April 1991
Jorge J. Gumucio, Adrian M. Di Bisceglie – 1 April 1991 – Fifty‐one patients with unresectable hepatocellular carcinoma were treated by embolization of the hepatic artery with Gelfoam powder, contrast material and three chemotherapeutic agents (doxorubicin, mitomycin, cisplatin). Twelve patients (24%) had a partial response with a decrease in the tumor diameter by at least 50%, 13 patients (26%) had only minor responses, 12 (24%) had stabilization of disease and the remainder had progressive disease.
Satoru Todo, Anthony J. Demetris, David van Thiel, Lewis Teperman, John J. Fung, Thomas E. Starzl – 1 April 1991 – Fifty‐nine patients with prior hepatitis B virus infection underwent orthotopic liver transplantation. During the first 2 mo, mortality was not significantly different in the hepatitis B virus–infected group (25.5%) vs. a hepatitis B virus–immune control group (21%). Beyond 2 mo, the mortality, rate of graft loss, need for retransplantation and incidence of abnormal liver function were significantly higher in the hepatitis B virus–infected group.